However, the findings of a more recent meta-analysis suggest that CD166 expression decreases the risk of vascular invasion (odds ratio 0.75; p = 0.017), and is not associated with overall survival, with the possible exception of stage II colorectal carcinoma [46]. This evidence concerns the gene ALCAM and colorectal carcinoma.